Advice
in the absence of a submission from the holder of the marketing authorisation:
ibrutinib (Imbruvica®) is not recommended for use within NHSScotland.
Indication under review: In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice355KB (PDF)
Medicine details
- Medicine name:
- ibrutinib (Imbruvica)
- SMC ID:
- SMC2244
- Indication:
In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.
- Pharmaceutical company
- Janssen-Cilag Ltd
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 November 2019